Brief: Vir Biotechnology Receives Expanded Support To Develop Its Novel T Cell Vaccine Platform With New $10 Million Grant For HIV Prevention
02/05/2023 15:16
May 2 (Reuters) - Vir Biotechnology Inc VIR.O :
* VIR BIOTECHNOLOGY RECEIVES EXPANDED SUPPORT TO DEVELOP ITS
NOVEL
T CELL VACCINE PLATFORM WITH NEW $10 MILLION GRANT FOR HIV
PREVENTION
* VIR BIOTECHNOLOGY - NEW GRANT FROM BILL & MELINDA GATES
FOUNDATION SUPPORTS PHASE 1 DEVELOPMENT OF VIR-1388
* VIR BIOTECHNOLOGY INC - PHASE 1 TRIAL OF VIR-1388 (HVTN
142) IS
EXPECTED TO BEGIN IN SECOND HALF OF 2023
Source text for Eikon: ID:nGNX2Xm0hb
Further company coverage: VIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO